Acumen Pharmaceuticals (ABOS) Competitors $1.40 +0.02 (+1.09%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ABOS vs. MBX, ACB, TERN, FHTX, TSHA, CYRX, ANNX, CRVS, TRVI, and CMPSShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), Cryoport (CYRX), Annexon (ANNX), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. MBX Biosciences Aurora Cannabis Terns Pharmaceuticals Foghorn Therapeutics Taysha Gene Therapies Cryoport Annexon Corvus Pharmaceuticals Trevi Therapeutics COMPASS Pathways MBX Biosciences (NYSE:MBX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Does the MarketBeat Community believe in MBX or ABOS? Acumen Pharmaceuticals received 21 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 71.43% of users gave Acumen Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesAcumen PharmaceuticalsOutperform Votes2571.43% Underperform Votes1028.57% Do institutionals and insiders believe in MBX or ABOS? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate MBX or ABOS? MBX Biosciences presently has a consensus target price of $37.25, indicating a potential upside of 242.37%. Acumen Pharmaceuticals has a consensus target price of $9.33, indicating a potential upside of 569.06%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is MBX or ABOS more profitable? MBX Biosciences' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Acumen Pharmaceuticals N/A -32.99%-27.99% Does the media refer more to MBX or ABOS? In the previous week, MBX Biosciences had 6 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 6 mentions for MBX Biosciences and 0 mentions for Acumen Pharmaceuticals. MBX Biosciences' average media sentiment score of 1.62 beat Acumen Pharmaceuticals' score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Overall Sentiment MBX Biosciences Very Positive Acumen Pharmaceuticals Neutral Which has better earnings & valuation, MBX or ABOS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AAcumen PharmaceuticalsN/AN/A-$52.37M-$1.38-1.01 SummaryMBX Biosciences and Acumen Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.81M$3.12B$5.77B$8.95BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-1.0130.1126.4618.81Price / SalesN/A319.76449.1576.64Price / CashN/A183.5344.0437.47Price / Book0.303.567.634.64Net Income-$52.37M-$71.72M$3.18B$245.69M7 Day Performance-3.79%-2.45%-1.82%-2.63%1 Month Performance-14.42%0.36%0.22%-2.37%1 Year Performance-58.36%-11.50%17.49%13.65% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals2.4314 of 5 stars$1.40+1.1%$9.33+569.1%-58.4%$83.81MN/A-1.0120MBXMBX Biosciences2.59 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoverageACBAurora Cannabis0.5175 of 5 stars$6.31-4.7%N/A+73.2%$346.17M$200.35M126.231,073Gap UpTERNTerns Pharmaceuticals4.3932 of 5 stars$4.06-0.5%$18.30+350.7%-50.4%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.7039 of 5 stars$6.13-0.5%$13.17+114.8%-12.4%$340.89M$34.15M-3.19120Positive NewsTSHATaysha Gene Therapies2.5091 of 5 stars$1.63+0.6%$6.63+306.4%-36.1%$334.05M$15.45M2.59180CYRXCryoport2.5802 of 5 stars$6.73+0.4%$12.29+82.6%-61.4%$332.66M$233.26M-1.991,170Positive NewsANNXAnnexon2.5512 of 5 stars$3.07+2.0%$15.80+414.7%-42.8%$327.23MN/A-2.9260News CoverageGap UpCRVSCorvus Pharmaceuticals1.9049 of 5 stars$4.88-0.8%$12.38+153.6%+82.2%$313.59MN/A-5.2530News CoverageTRVITrevi Therapeutics2.7475 of 5 stars$4.07+1.5%$9.31+128.8%+73.6%$312.86MN/A-9.2520News CoveragePositive NewsGap UpCMPSCOMPASS Pathways1.7049 of 5 stars$4.57+3.4%$30.60+569.6%-57.6%$312.68MN/A-2.08120 Related Companies and Tools Related Companies MBX Competitors ACB Competitors TERN Competitors FHTX Competitors TSHA Competitors CYRX Competitors ANNX Competitors CRVS Competitors TRVI Competitors CMPS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABOS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
